[Skip to Content]
[Skip to Content Landing]
Views 453
Citations 0
Observation
September 10, 2020

Presumed Chloroquine Retinopathy With Short-Term Therapy for Glioblastoma Multiforme

Author Affiliations
  • 1Department of Ophthalmology, Columbia University Irving Medical Center, New York, New York
  • 2Jonas Children’s Vision Care, New York, New York
  • 3Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
  • 4Weill Cornell Medical College, New York, New York
  • 5State University of New York at Downstate Medical Center, Brooklyn
  • 6Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York
  • 7Harkness Eye Institute, Columbia University Medical Center, New York, New York
JAMA Ophthalmol. Published online September 10, 2020. doi:10.1001/jamaophthalmol.2020.3251

Chloroquine and its analogue, hydroxychloroquine, are well-known antimalarial medications that are commonly used to treat systemic lupus erythematosus, rheumatoid arthritis, and various other autoimmune conditions.1 Recently, chloroquine has been used as an adjunct therapy in the treatment of several aggressive cancers, including glioblastoma multiforme.2 An important adverse effect of long-term chloroquine or hydroxychloroquine therapy is substantial and irreversible visual acuity loss accompanied by night blindness, which consequently necessitates careful ophthalmologic screening to prevent drug toxicity and retinal damage.1 In this report, we describe a case of acute-onset visual field loss in a 31-year-old woman treated with high-dose chloroquine therapy for glioblastoma multiforme.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×